

डॉ.राजीव सिंह रघुवंशी
सचिव-सह-वैज्ञानिक निदेशक

Dr. Rajeev Singh Raghuvanshi
Secretary-cum-Scientific Director

File No.IPC/NFI/2023/F-01

Dated 20th October, 2023

Subject: Errata-01 to National Formulary of India (NFI) 2021

The 6th edition, NFI 2021 was released on 28.10.2021. Based on the observations and inputs received, page numbers of some monographs in the section 'List of medicines monographs in NFI' and editorial mistake in a monograph need amendment. Accordingly, an Errata-01 to NFI 2021 is being issued containing such amendments and shall become effective with immediate effect.


(Dr. Rajeev Singh Raghuvanshi)

Errata-01 to NFI 2021

1. **Albendazole, at S. No. 15, Page. XXVII**
Change from: 189
to: 187
2. **Intraperitoneal Dialysis Solution at S.No. 257, Page. XXXVI**
Change from: 293
to: 430
3. **Paracetamol (Acetaminophen), at S.No. 382, Page. XLI**
Change from: 267
to: 16
4. **Pyrazinamide, at S.No. 418, Page. XLII**
Change from: 217
to: 218
5. **Raltegravir, at S. No. 423, Page. XLII**
Change from: 243
to: 244
6. **Ribavirin, at S.No. 430, Page. XLII**
Change from: 258
to: 259
7. **Rifabutin, at S.No. 431, Page. XLII**
Change from: 218
to: 219

8. **6.2 Laxatives /Cathartics/Purgatives** Page. 81

Point No. 1

Delete following Line

“of water, may cause dehydration, contraindicated in patient with compromised renal functions”

9. **6.2 Laxatives /Cathartics/Purgatives.** Page. 82

Point No.2 Bulk Forming, line 9

Change **from:** id

to: is

10. **Antiemetics.** Page. 113

Classification, Point No. 6

Delete: Delete one word “Antipsychotics”

11. **Domperidone.** Page No. 113

Dose

Change **from:** 10 to 20 g

to: 10 to 20 mg

12. **Metoclopramide.**Page No.115

Adverse effects, line 3

Change **from:** hyperprolactinemia

to: hyperprolactinemia

13. **Chloramphenicol.** Page No. 144

Note

Change **from:** other indication

to: other indication

14. **Ciprofloxacin.** Page No. 146

Note

Change **from:** other indication

to: other indication

15. **Cloxacillin.** Page No. 149

Contraindications

Change **from:** Hypersensitivity to penicillins (see notes above).
to: Hypersensitivity to penicillins (refer to page 126).

16. **Cloxacillin.** Page No. 149

Precautions

Delete: (see notes above)

17. **Doxycycline.** Page No. 152

Note

Change **from:** other indication
to: other indication

18. **Gentamicin.** Page No. 154

Note

Change **from:** other indication
to: other indication

19. **Metronidazole.** Page No. 160

Note

Change **from:** other indication
to: other indication

20. **Tetracycline.** Page No. 171

Note

Change **from:** other indication
to: other indication

21. **Mucocutaneous Leishmaniasis.** Page No. 191

Para 1, last line

Change **from:** outset
to: onset

22. Mucocutaneous Leishmaniasis. Page No. 191

Para 2, last line

Change **from:** disfigurings cars
to: disfiguring scars

23. Miltefosine. Page No. 191

Dose, line 6 & 10

Change **from:** miltefosin
to: miltefosine

24. Arterolane + Piperazine. Page No. 200

Dose, line 1

Change **from:** Arteronale
to: Arterolane

25. Quinine. Page No. 201

Precautions, line 1

Change **from:** A trial fibrillation'
to: Atrial fibrillation'

26. Rifampicin. Page No. 209

Note

Change **from:** other indiacation
to: other indication

27. Rifampicin. Page No. 221

Note

Change **from:** other indiacation
to: other indication

28. Acyclovir. Page No. 257

Note

Change **from:** other indiacation
to: other indication

29. Paracetamol. Page. 267

Change **from:** Refer Page No. 162

to: Refer Page No. 16

30. Capecitabin. Page. 280

Change **from:** Capecitabin

to: Capecitabine